yzj-4729
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Oct 12, 2022 (NCT06681493)
Timeline
Indications
Mechanism of action
- Mu-opioid receptorAGONIST
Q8CGM4 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06901830 | Phase 2 | Apr 30, 2025 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
| NCT06890533 | Phase 3 | Apr 30, 2025 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
| NCT06680466 | Phase 2 | Dec 26, 2023 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
| NCT06681493 | Phase 1 | Oct 12, 2022 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | For profit | 4 | 4 | 3 | 2022 |
1 organizations
Page 1 / 1